โ† All ACE Flashcard Decks

Program Management & Optimization Flashcards

7 cards from real ACE practice questions. Tap to flip, then mark Knew It or Still Learning โ€” missed cards come back until you master them.

Read the first 7 Program Management & Optimization flashcards as text
  1. A 340B program manager is reviewing quarterly utilization reports and notices a significant drop in 340B capture rate. What is the most appropriate first step?

    Answer: Analyze claims data to identify where eligible prescriptions are being missed

    Analyzing claims data is the foundational step to identify gaps in eligibility identification, dispensing workflows, or data accumulation before implementing solutions.

  2. Which of the following best describes the 'accumulation' step in a 340B contract pharmacy model?

    Answer: The tracking and crediting of 340B-eligible prescriptions dispensed at a contract pharmacy

    Accumulation refers to identifying 340B-eligible prescriptions dispensed at a contract pharmacy and building a replenishment credit that the covered entity uses to reorder drugs at 340B pricing.

  3. Under Apexus guidelines, which factor most directly determines whether a patient qualifies as a '340B patient' for an outpatient clinic encounter?

    Answer: Whether the covered entity has a healthcare relationship with the patient and is responsible for their care

    The 340B patient definition requires that the covered entity have an established healthcare relationship with the patient and maintain responsibility for that patient's care.

  4. A hospital's 340B program is being expanded to include an off-site clinic. What is the required action before the clinic can participate in 340B drug purchases?

    Answer: Register the child site with HRSA during an open enrollment period

    Off-site outpatient facilities must be registered with HRSA as child sites during an enrollment period before they are eligible to participate in 340B drug purchasing.

  5. Which internal control is most effective at preventing 340B drug diversion to ineligible patients?

    Answer: Implementing a robust patient eligibility verification process at the point of prescribing

    Verifying patient eligibility at the point of prescribing ensures that 340B drugs are reserved for patients who meet the program definition, the most upstream and effective control.

  6. What is the significance of the 'ceiling price' in the 340B drug pricing program?

    Answer: It is the maximum price manufacturers may charge covered entities for covered outpatient drugs

    The 340B ceiling price is calculated by statute as the average manufacturer price minus the Medicaid rebate percentage, and manufacturers cannot charge covered entities more than this amount.

  7. A covered entity's program manager wants to benchmark their 340B savings against peer organizations. Which source would provide the most relevant benchmarking data?

    Answer: Apexus 340B University and industry benchmarking reports

    Apexus, as the HRSA-designated Prime Vendor Program contractor, provides 340B-specific educational resources and benchmarking tools tailored to covered entity program management.